FOXP3 Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes
Table 3
Correlation analysis of FOXP3 polymorphisms in relation to prognostic parameters in total BC sample and aggressive subtypes.
Clinical outcomes
Total BC (tau)
Breast cancer subtypes [p (tau)]
LB
HER2+
TN
g.10403A>G
TNM staging
0.173 (τ = 0.11)
0.608 (τ = 0.08)
0.835 (τ = −0.04)
0.032 (τ = 0.23)
Tumor size
0.633 (τ = −0.04)
0.885 (τ = 0.02)
0.778 (τ = 0.05)
0.422 (τ = −0.10)
Ki-67
0.270 (τ = 0,11)
0.837 (τ = 0.04)
0.019 (τ = 0.47)
0.536 (τ = 0.08)
Histological grade
0.268 (τ = −0.10)
0.846 (τ = −0.03)
0.061(τ = −0.36)
0.909 (τ = −0.02)
LP commitment
0.298 (τ = 0.09)
0.337 (τ = 0.15)
0.175(τ = 0.255)
0.934 (τ = −0.01)
g.8048A>C
TNM staging
0.966 (τ = −0.003)
0.894 (τ = 0.02)
0.167 (τ = 0.23)
0.084(τ = −0.23)
Tumor size
0.166 (τ = 0.10)
0.403 (τ = 0.11)
0.912 (τ = −0.02)
0.419(τ = 0.10)
Ki-67
0.557 (τ = −0.06)
0.28 (τ = −0.21)
0.018 (τ = −0.47)
0.708 (τ = 0.05)
Histological grade
0.135 (τ = −0.15)
0.754 (τ = 0.06)
0.026 (τ = 0.39)
0.927 (τ = 0.01)
LP commitment
0.895 (τ = −0.01)
0.662 (τ = −0.07)
0.811(τ = −0.05)
0.913 (τ = 0.02)
Kendall’s tau test; value of was considered statistically significant. BC: breast cancer; LB: Luminal B HER2+; HER2+: HER2-enriched; TN: triple-negative; LP: lymph node.
